Exelixis, Inc. - Common Stock (NQ:EXEL)

59.02 +0.58 (+0.99%)

Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

June 21, 2022

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis-BioInvent Establish Immuno-Oncology Pact ↗

June 16, 2022

Via Benzinga

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

June 16, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June

May 31, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022

May 26, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

May 26, 2022

From Exelixis, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ↗

May 24, 2022

Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!

Via InvestorPlace

This Biotech Looks Good With Increased M&A activity ↗

May 20, 2022

Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 19, 2022

Via Benzinga

Exelixis: Q1 Earnings Insights ↗

May 10, 2022

Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by...

Via Benzinga

Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 10, 2022

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May

May 04, 2022

From Exelixis, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

May 03, 2022

From Exelixis, Inc.

Via Business Wire

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer ↗

May 03, 2022

Via Benzinga

Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022

April 26, 2022

From Exelixis, Inc.

Via Business Wire

7 Top-Rated Biotech Stocks to Buy for Q2 ↗

April 21, 2022

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

Via InvestorPlace

Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

April 14, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors

April 13, 2022

From Exelixis, Inc.

Via Business Wire

Friday Markets News ↗

March 25, 2022

Methane leaks in the Permian Basin are 6 times higher than estimates.

Via Talk Markets

EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer ↗

March 25, 2022

Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have

Via Benzinga

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

March 25, 2022

From Exelixis, Inc.

Via Business Wire

Flood Helping Ukraine ↗

March 24, 2022

Emerging markets are gaining as mature markets look risky.

Via Talk Markets

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer

March 14, 2022

From Exelixis, Inc.

Via Business Wire

Futures Flat As Traders Brace For Op-Ex Volatility, More Ukraine Headlines ↗

February 18, 2022

In the latest geopolitical developments Russian Foreign Minister Sergei Lavrov agreed to meet US Secretary of State Antony Blinken for talks in Europe next week; German Chancellor Olaf Scholz will host...

Via Talk Markets

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.